Phaseline

Companies › Exciva

Exciva: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 3 Phase 2, 3 Phase 1; Neurology, Oncology, Other, Psychiatry; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dextromethorphan (EXV-802)
Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist
SIGMAR1, GRIN2APhase 2Agitation Associated With Alzheimer's Disease Dementia; Obsessive-Compulsive Disorder; Hodgkin Lymphoma; Psychedelic Effects in Healthy Volunteers …Jan 2029
EXV-801
Sigma-1 receptor agonist
SIGMAR1Phase 2Agitation Associated With Alzheimer's Disease DementiaJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06383338Dextromethorphan (EXV-802)Phase 1Hodgkin LymphomaOncologyNov 2026
NCT04899687Dextromethorphan (EXV-802)Phase 2Obsessive-Compulsive DisorderPsychiatryApr 2027
NCT06772753Dextromethorphan (EXV-802)Phase 1Psychedelic Effects in Healthy VolunteersOtherJun 2027
NCT07284472Dextromethorphan (EXV-802)Phase 2Agitation Associated With Alzheimer's Disease DementiaNeurologyJan 2029
NCT07284472EXV-801Phase 2Agitation Associated With Alzheimer's Disease DementiaNeurologyJan 2029
NCT07593222Dextromethorphan (EXV-802)Phase 1Major DepressionPsychiatryDec 2030

Targets

SIGMAR1 (2) GRIN2A (1)

Companies with the same targets

CSPC Ouyi Pharmaceutical UCB BIOSCIENCES Anavex Life Sciences Pentixapharm Zogenix Syndeio Biosciences SHINKEI Therapeutics Aptinyx Johnson & Johnson (Janssen)

Companies built like this

Aptinyx SHINKEI Therapeutics Syndeio Biosciences Spinogenix Shanghai Auzone Biological Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.